Mansouri Kaweh, Ravinet Emilie
Glaucoma Unit, Jules Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland.
Clin Exp Ophthalmol. 2009 Apr;37(3):286-92. doi: 10.1111/j.1442-9071.2009.02030.x.
To evaluate effects of mitomycin-C (MMC) in deep sclerectomy with collagen implant applied under the superficial scleral flap or under the deep scleral flap.
Twenty-five patients with primary or secondary open-angle glaucoma and at high risk for postoperative cicatrization underwent deep sclerectomy and were randomly distributed to the two treatment arms. In the superficial MMC group (S-MMC), MMC was applied under the superficial scleral flap using a soaked sponge for 60 s; in the deep MMC group (D-MMC), MMC was applied under the deep scleral flap for 60 s before entering the Schlemm's canal. In both groups, remaining MMC was irrigated with 40 mL balanced salt solution. Patients were followed up for up to 2 years. The volume of filtering blebs was studied with ultrasound biomicroscopy at the last follow-up visit.
Mean preoperative intraocular pressure (IOP) was 20.5 +/- 8.9 mmHg for D-MMC and 21.6 +/- 6.6 mmHg for S-MMC eyes (P = 0.67). The mean postoperative IOP was 5.3 +/- 3.3 mmHg (D-MMC) and 6.9 +/- 4.8 mmHg (S-MMC) at day 1 (P = 0.22) and 11.4 +/- 6.3 mmHg (D-MMC) versus 11.3 +/- 4.6 mmHg (S-MMC) at last follow up (P = 0. 54). The mean number of medications per patient was reduced from 2.5 +/- 0.5 to 0.4 +/- 0.5 (D-MMC) (P < 0.001) and from 2.5 +/- 0.9 to 0.3 +/- 0.4 (S-MMC) (P < 0.001). Ultrasound biomicroscopy at 24 months showed mean intrascleral space volume of 1.97 +/- 0.35 mm3 (D-MMC) and 5.68 +/-0.42 mm3 (S-MMC) (P < 0.05).
No significant difference in efficacy and safety was found between the two groups at a mean of 19.2 months of follow up. Deep scleral application of MMC, however, seems to produce significantly smaller intrascleral blebs.
评估丝裂霉素-C(MMC)在浅层巩膜瓣或深层巩膜瓣下应用胶原植入物的深层巩膜切除术中的效果。
25例原发性或继发性开角型青光眼且术后有高瘢痕化风险的患者接受了深层巩膜切除术,并随机分为两个治疗组。在浅层MMC组(S-MMC)中,使用浸湿的海绵在浅层巩膜瓣下应用MMC 60秒;在深层MMC组(D-MMC)中,在进入施莱姆管之前在深层巩膜瓣下应用MMC 60秒。两组均用40毫升平衡盐溶液冲洗残留的MMC。对患者进行长达2年的随访。在最后一次随访时用超声生物显微镜研究滤过泡的体积。
D-MMC组术前平均眼压(IOP)为20.5±8.9 mmHg,S-MMC组眼为21.6±6.6 mmHg(P = 0.67)。术后第1天,D-MMC组平均眼压为5.3±3.3 mmHg,S-MMC组为6.9±4.8 mmHg(P = 0.22),最后一次随访时,D-MMC组为11.4±6.3 mmHg,S-MMC组为11.3±4.6 mmHg(P = 0.54)。每位患者的平均用药数量从2.5±0.5减少到0.4±0.5(D-MMC)(P < 0.001),从2.5±0.9减少到0.3±0.4(S-MMC)(P < 0.001)。24个月时的超声生物显微镜检查显示,D-MMC组巩膜内间隙平均体积为1.97±0.35立方毫米,S-MMC组为5.68±0.42立方毫米(P < 0.05)。
在平均19.2个月的随访中,两组在疗效和安全性方面未发现显著差异。然而,在深层巩膜应用MMC似乎会产生明显更小的巩膜内滤过泡。